<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880980</url>
  </required_header>
  <id_info>
    <org_study_id>PEMH Rawalpindi</org_study_id>
    <nct_id>NCT04880980</nct_id>
  </id_info>
  <brief_title>Comparison of Efficacy of Double Dose Oral Terbinafine Vs Itraconazole in Treatment of Dermatophyte Infections of Skin.</brief_title>
  <official_title>Comparison of Efficacy of Double Dose Oral Terbinafine Versus Itraconazole in Treatment of Dermatophyte Infections of Skin - A Prospective, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pak Emirates Military Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pak Emirates Military Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study would be conducted to compare the efficacy and safety of double than usual dose oral&#xD;
      terbinafine versus itraconazole in treatment of dermatophyte infections of skin in patient&#xD;
      presenting at dermatology department of Pak Emirates Military Hospital, Rawalpindi, Pakistan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Study would be a randomized controlled trial, in which 60 subjects would be randomly&#xD;
           divided into two equal groups of 30 each.&#xD;
&#xD;
        -  Each group would be prescribed double than usual dose of terbinafine(250 mg twice daily)&#xD;
           or itraconazole(100mg twice daily) for 2 weeks initially. Treatment may be extended to 4&#xD;
           weeks if cure has not been achieved.&#xD;
&#xD;
      Patients will be diagnosed and followed on the basis of classical clinical features of&#xD;
      dermatophyte infections and microscopic potassium hydro-oxide slide preparation for fungal&#xD;
      hyphae and spores.&#xD;
&#xD;
      Liver function tests will be checked on day 0, 14 and 28. Individuals aged 15-50 years with&#xD;
      one or no co-morbidity will be included in the study.&#xD;
&#xD;
      Study will be conducted over a period of 6-8 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be randomly assigned to group one or two.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients cured by using double dose of oral terbinafine Vs itraconazole in the treatment of resistant dermatophyte skin infections as assessed by measuring pruritis, erythema and scaling .</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Classical clinical features of dermatophyte skin infections (pruritis, erythema and scaling, all will be graded on a scale 0-3 i. e 0=none to 3=severe) would be noted at start of treatment after 2 weeks and then if required after 4 weeks of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse effects including effects on liver function tests of double dose oral terbinafine Vs itraconazole in the treatment of resistant dermatophyte skin infections.</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Objective Assessment of adverse effects (nausea, vomiting, jaundice) as well as laboratory evaluation of liver function tests (Bilirubin umol/L, ALT U/L, ALP U/L) would be performed at start of treatment after 2 weeks and if required than after 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment required to achieve cure from resistant dermatophyte infections.</measure>
    <time_frame>2-4 weeks</time_frame>
    <description>Treatment response in form of clinical features (changes in erythema. Pruritis and scaling) and KOH fungal slide smear testing would be done after 2 weeks of treatment and if required than after 4 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dermatophyte Infection</condition>
  <condition>Terbinafine Adverse Reaction</condition>
  <condition>Itraconazole Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Efficacy of double dose oral terbinafine in treatment of dermatophytic infections of skin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of participants will be given double than usual dose of oral terbinafine for the treatment of dermatophyte skin infections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efficacy of double dose oral itraconazole in treatment of dermatophytic infections of skin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of participants will be given double than usual dose of oral itraconazole for the treatment of dermatophyte skin infections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terbinafine Pill</intervention_name>
    <description>Double than usual dose of oral terbinafine pills will be used for treatment purpose in one group.</description>
    <arm_group_label>Efficacy of double dose oral terbinafine in treatment of dermatophytic infections of skin</arm_group_label>
    <other_name>Lamisil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole capsule</intervention_name>
    <description>Double than usual dose of oral itraconazole capsules will be used for treatment purpose in second group.</description>
    <arm_group_label>Efficacy of double dose oral itraconazole in treatment of dermatophytic infections of skin</arm_group_label>
    <other_name>Icon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  individuals with dermatophyte skin infection, aged 15-50 years with one or no&#xD;
             co-morbidities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  individuals with two or more co-morbidities or known cases of chronic liver disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Umar Abdul Ali Qureshi, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pak Emirates Military Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Umar Abdul Ali Qureshi, MBBS</last_name>
    <phone>+923325135953</phone>
    <email>umar_siddique_786@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pak Emirates Military Hospital</name>
      <address>
        <city>Rawalpindi</city>
        <state>Punjab</state>
        <zip>46000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Umar Abdul Ali Qureshi, MBBS</last_name>
      <phone>+923325135953</phone>
      <email>umar_siddique_786@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Umar Abdul Ali Qureshi, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pak Emirates Military Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Umar Abdul Ali Qureshi</investigator_full_name>
    <investigator_title>Speciality Registrar Dermatology</investigator_title>
  </responsible_party>
  <keyword>double dose</keyword>
  <keyword>oral terbinafine</keyword>
  <keyword>oral itraconazole</keyword>
  <keyword>dermatophyte skin infection</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Dermatomycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Terbinafine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant's data will be kept confidential.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

